Athira Pharma Provides 2023 Pipeline Outlook
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects
Related news for (ATHA)
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/03/25 05:00 AM
- Today’s Top Performers: MoBot’s Market Review 06/03/25 04:00 AM
- Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
- Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
- Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
